Post operative regrowth of aggressive Brain Tumour.?

Question

After operation of a benign brain tumour (aggressive) in May 2006, MRI scan detected some regrowth (2.5cm) in March 2007. What will be the future course of treatment ?

Answer 1

Of course there is, go in for neurosurgery, this is not only important to remove the disease but will also contribute to histopathology, mostly lowa grade brain tumors become high grade in due course of time.
The treatment differs for them, but how will you know unless we have histopathology.
Nevertheless best outcome of brain tumors are with surgery followed by adjuvant treatment if any required. U may email me with details

Answer 2

My brother had malignant brain cancer. After he had most of the cancer removed, he had a combination of radiation and chemo. As yours was a bening growth --course of action would probably be the similar either one or the other or a combination of both radiation and/or chemo. I am not a doctor. You might want to get the opinions of one or two additional specialists in this field. Good luck to you. Stay away from herbal remedies and chemo as there is almost always an interaction.

Answer 3

Most posters are correct. It depends on your situation (location, tumor grade, overall physical health, age, etc.).

Some possibilities are:
1) Additional surgery to debulk the tumor
2) Treatment with radiation. Most likely sterotactic like the gamma knife.
3) Chemotherapy usually oral like Procarbazine or Temodar
4) Clinical trials which may include surgery, radiation, chemotherapy, immunotherapy (vaccines), targeted therapies (anti-angiogenesis drugs) and/or other approaches (i.e.Tamoxifen is being used in clinical trials now for low grade gliomas).

Answer 4

Even with benign tumors, they will often do some radiation, combined with chemotherapy agents that increase the effectiveness of the radiation. Such drugs end in "platin" such as cisplatin

Answer 5

Mechanisms Involved With Tumor Relapse Identified

Science Daily — Research could lead to the development of cancer vaccines.

Researchers at Virginia Commonwealth University's Massey Cancer Center studying the interaction between the immune system and cancer cells have identified interferon gamma as one of the signaling proteins involved with tumor relapse.

The findings may help researchers develop tailored vaccines and other immunotherapeutic strategies to fight a number of cancers. Immunotherapy involves the manipulation of the immune system – by introducing an antibody or lymphocytes, or immunization with a tumor vaccine – to recognize and eradicate tumor cells.

Using a transgenic mouse model of breast cancer, researchers found that interferon gamma, a cytokine or chemical messenger that is produced by cells of the immune system upon activation, plays a role in tumor relapse. In humans, interferon gamma is also produced by white blood cells of the immune system in response to invasion by pathogens or tumors in order to protect the host against infection or cancers.

Production of interferon gamma by lymphocytes against tumors is considered a sign of good prognosis; however, recent study findings indicate that this may not be the case. The findings were reported in the European Journal of Immunology, the official journal of the European Federation of Immunological Societies.

"By understanding the molecular mechanisms involved with tumor relapse, we can create tailored vaccines that can induce specific types of immune responses in patients, rather than inducing a broad range of immune responses - some of which may be detrimental or may induce tumor relapse," said lead investigator, Masoud H. Manjili, D.V.M., Ph.D., a member scientist with the Massey Cancer Center.

"Ultimately, we hope to offer a new polypeptide vaccine approach that induces tumor killing without causing HER-2/neu loss. Loss of HER-2/neu is a mechanism that tumors utilize to escape the immune-mediated destruction," he said.

Since 2000, Manjili and his colleagues have been employing animal models of breast cancer to evaluate anti-tumor efficacy of a vaccine formulation they created. This vaccine formulation combines a heat shock protein 110 (HSP110), as an adjuvant, with a tumor antigen HER-2/neu, as a protein target expressed in breast tumors. Adjuvants are agents that are able to modify another agent – basically working as a chemical catalyst.

Answer 6

There is a testimonial of a person with a brain tumor that is currently doing a cure, posted at this web site.

http://geocities.com/cure.cancer/

Answer 7

Whether you have gone through chemotherapy.It is best way to retard growth of tumour